Cowen analyst Dan Brennan raised the firm’s price target on 10x Genomics to $57 from $52 and keeps an Outperform rating on the shares. The analyst said the 4Q results beat and noted 2023 guide met expectations and creates a better set up.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TXG:
- 10x Genomics reports Q4 EPS (15c), consensus (31c)
- 10x Genomics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Outlook for 2023
- Singular Genomics showcases G4 sequencing data with 11 genomics partners
- Singular Genomics joins 10x Genomics Compatible Partner Program
- 10x Genomics initiated with a Neutral at UBS